HomeCompareOCX vs QSR

OCX vs QSR: Dividend Comparison 2026

OCX yields 62.50% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCX wins by $711.3K in total portfolio value
10 years
OCX
OCX
● Live price
62.50%
Share price
$3.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$735.9K
Annual income
$177,443.13
Full OCX calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — OCX vs QSR

📍 OCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCXQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCX + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCX pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCX
Annual income on $10K today (after 15% tax)
$5,312.50/yr
After 10yr DRIP, annual income (after tax)
$150,826.66/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, OCX beats the other by $150,496.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCX + QSR for your $10,000?

OCX: 50%QSR: 50%
100% QSR50/50100% OCX
Portfolio after 10yr
$380.3K
Annual income
$88,915.50/yr
Blended yield
23.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on OCX right now

OCX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Price Target
$8.06
+151.9% upside vs current
Range: $4.25 — $10.00
Altman Z
-27.0
Piotroski
2/9
QSR
No analyst data
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCX buys
0
QSR buys
0
No recent congressional trades found for OCX or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCXQSR
Forward yield62.50%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$735.9K$24.7K
Annual income after 10y$177,443.13$387.88
Total dividends collected$614.9K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: OCX vs QSR ($10,000, DRIP)

YearOCX PortfolioOCX Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$16,950$6,250.00$11,038$337.57+$5.9KOCX
2$28,037$9,900.70$12,156$345.43+$15.9KOCX
3$45,305$15,305.49$13,359$352.69+$31.9KOCX
4$71,591$23,114.13$14,654$359.36+$56.9KOCX
5$110,737$34,135.17$16,045$365.45+$94.7KOCX
6$167,835$49,346.36$17,539$370.97+$150.3KOCX
7$249,481$69,897.34$19,143$375.96+$230.3KOCX
8$364,047$97,102.68$20,863$380.42+$343.2KOCX
9$521,955$132,424.34$22,708$384.39+$499.2KOCX
10$735,935$177,443.13$24,685$387.88+$711.3KOCX

OCX vs QSR: Complete Analysis 2026

OCXStock

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Full OCX Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this OCX vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCX vs SCHDOCX vs JEPIOCX vs OOCX vs KOOCX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.